Clinical Trial ECOGHEMS1203


A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)

Principal Investigator(s)

Stephen Strickland


  • Protocol No. ECOGHEMS1203
  • Open Date: 07/26/2013
  • Staging: Phase III
  • Age Group: Adults
  • Scope: National
  • Objective: a. (Chemotherapy): To compare event-free survival (EFS) between patients with AML who receive standard 7+3 or idarubicin and high-dose cytarabine (IA) to patients who receive IA + vorinostat. b. (Transplant): To determine whether it is possible to get 60% or more of adults with high-risk AML in first complete
  • Disease Sites: Leukemia
  • Therapies: Chemotherapy - cytotoxic
  • Drugs: AraC; Daunorubicin (Daunomycin); Idarubicin; Vorinostat (ZOLINZA)
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: 01802333
  • Secondary Protocol No: S1203